Daewon Pharmaceutical Begins In-House Production of Osteoarthritis Treatment "Shinbaro"

Co-promotion Began in 2018, Asset Acquisition in 2024

Unified Production and Sales System Established

Approximately 5 Billion Won Invested to Expand Production Facilities

Securing a Stable Supply Foundation

Daewon Pharmaceutical has begun in-house production of its natural medicine for osteoarthritis treatment, Shinbaro Tablets.

On September 21, Daewon Pharmaceutical announced that it has established a system to directly handle the entire process of Shinbaro, from production to distribution, marketing, and sales.

Advertisement for Shinbaro Tablets, an osteoarthritis treatment by Daewon Pharmaceutical. Daewon Pharmaceutical

Shinbaro, introduced in 2011 as Korea's fourth domestically developed natural medicine, is used for anti-inflammatory, analgesic, and osteoarthritis treatment. In 2018, Daewon Pharmaceutical entered into a co-promotion agreement with GC Green Cross and has since been responsible for domestic distribution, marketing, and sales. In 2024, the company signed an asset transfer agreement to acquire the related assets, including the product manufacturing and sales license.

Since January 2025, Daewon Pharmaceutical has been operating Shinbaro as its own product. With the recent move to in-house production, the company is now directly responsible for manufacturing as well.

To facilitate the transition to in-house production, Daewon Pharmaceutical invested approximately 5 billion won to expand its production facilities. The company plans to respond to market demand by linking production and sales, while also aiming to enhance quality control and operational efficiency to ensure stable product supply.

A representative from Daewon Pharmaceutical stated, "With in-house production, we have established an autonomous system that covers every stage from production to sales for Shinbaro. Through securing a stable supply chain and strengthening product competitiveness, we aim to make Shinbaro a key item in the musculoskeletal treatment market."

This content was produced with the assistance of AI translation services.